Ireland
--:--IST
Recruiting Not applicable

Evaluation of the Efficacy of "Lifespan Integration" (LI) Therapy in Patients With Complex Post-Traumatic Stress Disorder

NCT06535243 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2024-04-01
Last updated
2024-08-02

Condition(s) studied

Post-Traumatic Stress Disorder ComplexPsychiatric DisorderAbuse NeglectAbuse PhysicalAbuse, SexualAbuse DomesticAbuse Verbal

Investigational drug(s) / intervention(s)

Lifespan Integration Therapy (LI)

Lifespan Integration Therapy (LI): same as above

Study summary

The study aims to evaluate the efficacy of a relatively new type of psychotherapy called Lifespan Integration (LI) in patients suffering of complex PTSD

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * patients diagnosed with complex PTSD * French speaking * first time following an LI type of therapy * psychotropic treatment is allowed Exclusion Criteria: * no other parallel psychotherapy is accepted (if the patient underwent recently any other type of psychotherapy, a "wash out " period of minimum 4 weeks is required ) * no active manic episode at the time of inclusion * no active psychotic episode at the time of inclusion * no chronic psychotic disorder diagnosis * no autistic spectrum disorder diagnosis , * no intellectual deficit

Primary outcome measure(s)

  • change of the scores of International Trauma Questionnaire — maximum one year
    International Trauma Questionnaire measures subscores of simple and complex PTSD, the score is calculated using an algorithm, a minimum score of 8 for the PTSD simple part and of 8 for PTSD complex part is needed in order to diagnose a complex PTSD; the maximum score for simple PTSD is 16, same for complex PTSD.

Trial sites (1)

FacilityCityRegionStatus
CHU St Anne Paris Île-de-France Region Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06535243 on ClinicalTrials.gov ↗ ← All trials in France